ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients
Study in The Lancet Shows No Safety Concerns and Improved Vision in Patients with Macular Degeneration MARLBOROUGH, Mass. — Jan….
Study in The Lancet Shows No Safety Concerns and Improved Vision in Patients with Macular Degeneration MARLBOROUGH, Mass. — Jan….
Company Strengthens Clinical Team as it Nears Phase II Trials in AMD and SMD MARLBOROUGH, Mass. — December 12, 2013…
Worcester, MA – Michael D. West, Ph.D., President and Chief Scientific Officer of Advanced Cell Technology, Inc. (OTC Bulletin Board:…
Alan C. Shapiro, Ph.D., brings wealth of corporate and international financial management experience Worcester, MA – Advanced Cell Technology, Inc….
Company to Pursue Reverse Stock Split in Connection with National Exchange Listing MARLBOROUGH, Mass. — August 12th, 2013 – Advanced…
Company To Discuss Data as Part of Third Quarter Financial Results on Today’s Conference Call MARLBOROUGH, Mass. – November 8,…
MARLBOROUGH, Mass. — Advanced Cell Technology, Inc.(“ACT”; OTCBB: ACTC) today announced that Gary Rabin will leave the Chief Executive Officer position,…
Pioneering Stem Cell Studies for Treating Macular Degeneration Advance to Next Step MARLBOROUGH, Mass. — Sept. 28, 2011 – Advanced…
New Australian Patent Covers Human RPE Cells Made From Range of Pluripotent Stem Cells, Including Both Embryonic Stem Cells and…
Proxy Sets Record Date of March 1, 2012 and Annual Meeting Date of April 26, 2012 MARLBOROUGH, Mass. — March…